At Acumen, we are singularly focused on the development of targeted therapies for Alzheimer’s disease, a condition that has remained untreatable for far too long.
We are at a breakthrough moment for Alzheimer’s disease research and drug development.
Acumen is leveraging decades of learnings to deliver treatments FOR the benefit of everyone impacted by this devastating disease.
With passion, expertise, and perseverance, we are forging a path towards innovative treatments that preserve quality time for all people impacted by Alzheimer’s and other neurodegenerative diseases.
Our founders pioneered seminal discoveries and methods to understand the role of toxic soluble amyloid beta oligomers (AβOs) in synaptic dysfunction and neurodegeneration. Today, Acumen’s leaders are leveraging critical insights to advance the company and sabirnetug (ACU193) in the clinic and beyond.
Acumen acquires exclusive licenses to the Aβ-derived diffusible ligands (ADDLs) intellectual property of Northwestern University and University of Southern California.
Acumen and Merck & Co. enter exclusive license and research collaboration
ACU193 selected as pre-clinical candidate
Acumen receives ACU193 program exclusivity
National Institute of Aging awards $3.6 million U01 grant for development of ACU193
Former Lilly Alzheimer’s disease development team engaged,
Acumen closes on a $15 million Series A-1 round
Acumen closes on a $75 million Series B round
A first-in-human, Phase 1 clinical trial (INTERCEPT-AD) of sabirnetug (ACU193) in early Alzheimer’s disease patients initiated. Acumen becomes a publicly traded company (NASDAQ:ABOS) and hires first 14 employees
Acumen doubles the size of the organization to 34 employees and advances the INTERCEPT-AD trial, continues enrollment with projected top-line results in 2023
Acumen reports positive results from Phase 1 INTERCEPT-AD Trial presenting data at both AAIC and CTAD
We use two broad categories of cookies: (1) first party cookies, served directly by us to your computer or mobile device, which we use to recognize your computer or mobile device when it revisits our Sites; and (2) third party cookies, which are served by service providers or business partners on our Sites, and can be used by these parties to recognize your computer or mobile device when it visits other websites. Third party analytics cookies can be used for a variety of purposes, including analytics for site traffic, advertising, and social media features. Essential cookies are those that are used to allow for technical operation of the website platform and features.
Essential Website Cookies
These cookies are necessary to allow the technical operation of our Services (e.g., they enable you to move around on a website and to use its features).
Google Analytics Cookies
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visist to our site you can disable tracking in your browser here:
Other external services
We also use different external services like Google Webfonts, Google Maps and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.